Inhibition of Laryngeal Cancer Cell Invasion and Growth with Lentiviral-Vector Delivered Short Hairpin RNA Targeting Human MMP-9 Gene

REFERENCES

• Xie M., Sun Y., Li Y. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope 2004; 114: 2243–2248
   PubMed Web of Science ®Google Scholar
• Hojilla C. V., Mohammed F. F., Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003; 89: 1817–1821
   PubMed Web of Science ®Google Scholar
• Zucker S., Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101–117
   PubMed Web of Science ®Google Scholar
• O'Grady A., Dunne C., O'Kelly P., et al. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression. Histopathol 2007; 51: 793–804
   PubMed Web of Science ®Google Scholar
• Zheng H., Takahashi H., Murai Y., et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res 2006; 26: 3579–3583
   PubMed Web of Science ®Google Scholar
• Quaranta M., Daniele A., Coviello M., et al. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res 2007; 27: 3593–3600
   PubMed Web of Science ®Google Scholar
• Di Nezza L. A., Misajon A., Zhang J., et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer Mar 1, 2002; 94: 1466–1475
   PubMed Web of Science ®Google Scholar
• Franchi A., Santucci M., Masini E., et al. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 2002; 95: 1902–1910
   PubMed Web of Science ®Google Scholar
• Karavasilis V., Malamou-Mitsi V., Briasoulis E., et al. Matrix metalloproteinases in carcinoma of unknown primary. Cancer 2005; 104: 2282–2287
   PubMed Web of Science ®Google Scholar
• Fire A., Xu S., Montgomery M. K., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806–811
   PubMed Web of Science ®Google Scholar
• Chambers A. F., Matrisian L. M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260–1270
   PubMed Web of Science ®Google Scholar
• Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161–174
   PubMed Web of Science ®Google Scholar
• Sun Y. N., Xie M. Q., Liu M., et al. Growth suppression of human laryngeal squamous cell carcinoma by adenovirus-mediated tissue factor pathway inhibitor gene 2. Laryngoscope 2006; 116: 596–601
   PubMed Web of Science ®Google Scholar
• Gu W., Putral L., Hengst K., et al. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 2006; 13: 1023–1032
   PubMed Web of Science ®Google Scholar
• Sumimoto H., Hirata K., Yamagata S., et al. Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int J Cancer 2006; 118: 472–476
   PubMed Web of Science ®Google Scholar
• Kunigal S., Lakka S. S., Gondi C. S., et al. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 2007; 121: 2307–2316
   PubMed Web of Science ®Google Scholar
• Tummalapalli P., Gondi C. S., Dinh D. H., et al. RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis. Int J Oncol 2007; 3: 5–17
   Google Scholar
• Kondraganti S., Mohanam S., Chintala S. K., et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res. 2000; 60: 6851–6855
   PubMed Web of Science ®Google Scholar
• Levesque A. A., Eastman A. p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?. Carcinogen 2007; 28: 13–20
   PubMed Web of Science ®Google Scholar
• Xu J., Morris G. F. p53-mediated regulation of proliferating cell nuclear antigen expression in cells exposed to ionizing radiation. Mol Cell Biol 1999; 19: 12–20
   PubMed Web of Science ®Google Scholar
• Liu J., Zhan M., Hannay J. A., et al. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res 2006; 4: 803–810
   PubMed Web of Science ®Google Scholar
• Meyer E., Vollmer J. Y., Bovey R., et al. Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Cancer Res 2005; 65: 4261–4272
   PubMed Web of Science ®Google Scholar
• Yao J., Xiong S., Klos K., et al. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 2001; 20: 8066–8074
   PubMed Web of Science ®Google Scholar
• Rao J. S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003; 3: 489–501
   PubMed Web of Science ®Google Scholar
• Bergers G., Brekken R., McMahon G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737–744
   PubMed Web of Science ®Google Scholar